121 related articles for article (PubMed ID: 36935091)
1. Systemically inoculated adjuvants stimulate pDC-dependent IgA response in local site.
Sasaki E; Asanuma H; Momose H; Furuhata K; Mizukami T; Matsumura T; Takahashi Y; Hamaguchi I
Mucosal Immunol; 2023 Jun; 16(3):275-286. PubMed ID: 36935091
[TBL] [Abstract][Full Text] [Related]
2. Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines.
Ye L; Ohnemus A; Ong LC; Gad HH; Hartmann R; Lycke N; Staeheli P
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511392
[TBL] [Abstract][Full Text] [Related]
3. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
4. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
[TBL] [Abstract][Full Text] [Related]
5. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
[TBL] [Abstract][Full Text] [Related]
6. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
[TBL] [Abstract][Full Text] [Related]
8. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
9. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
[TBL] [Abstract][Full Text] [Related]
10. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
11. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.
Bracci L; Canini I; Venditti M; Spada M; Puzelli S; Donatelli I; Belardelli F; Proietti E
Vaccine; 2006 Apr; 24 Suppl 2():S2-56-7. PubMed ID: 16823927
[TBL] [Abstract][Full Text] [Related]
12. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
13. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
14. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
Front Immunol; 2019; 10():646. PubMed ID: 30984200
[TBL] [Abstract][Full Text] [Related]
15. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
Qin T; Yin Y; Huang L; Yu Q; Yang Q
Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
[TBL] [Abstract][Full Text] [Related]
16. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
Bracci L; Canini I; Puzelli S; Sestili P; Venditti M; Spada M; Donatelli I; Belardelli F; Proietti E
Vaccine; 2005 Apr; 23(23):2994-3004. PubMed ID: 15811645
[TBL] [Abstract][Full Text] [Related]
17. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
[TBL] [Abstract][Full Text] [Related]
18. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
20. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
